Gyala Therapeutics unveils first-in-class CAR-T therapy targeting CD84 showing strong preclinical efficacy in hard-to-treat leukemias

Leukemia publishes preclinical development results of CAR-T therapy GYA01 for acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia (T-ALL) Gyala secures €3 million financing from Invivo Partners, Nara Capital and CDTI Innvierte to launch a Phase I trial in AML patients in...